Where to buy the AMD Ryzen 9 9950X3D: new gaming CPUs at no extra cost
The day is finally here: AMD is adding to its list of best processors, and gamers have something to be happy about — they both have the same recommended list price (MSRP) as their last-gen counterparts.
The Ryzen 9 9950X3D and the Ryzen 9 9900X3D both feature AMD's famous 3D V-Cache tech that makes them gaming beasts, but unlike the 9800X3D, they sport more cores — making them better picks for productivity. The initial batch might sell out quickly, so check out where to get them once they go on sale today.
Several retailers have already listed the Ryzen 9 9000X3D CPUs, so if you're in the U.S., you've got a good chance of being able to snap one up.
Retailer
AMD Ryzen 9 9950X3D
AMD Ryzen 9 9900X3D
Best Buy
$699
$599
B&H Photo
$699 (TBA)
$599 (TBA)
Micro Center
$699.99
$599.99
Newegg
$699.99
$599.99
As far as specifications go, AMD stayed true to the formula it appears to have perfected in the previous generation; both CPUs have the exact same specs. This means 16 cores and 32 threads for the Ryzen 9 9950X3D and 12 cores for the Ryzen 9 9900X3D. The flagship sports 144MB of combined cache, while its cheaper counterpart offers 140MB.
Despite the lack of updates in the specs, the CPUs should get a significant boost from the update to Zen 5 and a newer 3D V-Cache. So far, reviewers highlight that the 9950X3D can match the 9800X3D in gaming, while rivaling the 9950X in productivity. This isn't a surprise — the same situation took place in the Ryzen 7000 generation, when the two CPUs to compare were the 7950X3D and the 7950X.
At the time of writing, some retailers are still yet to list the CPU, as the sales start at 6am PT / 9am ET. However, a few listings are already here for you to keep an eye on and refresh. Come back here a little bit later to see an updated list of AMD Ryzen 9 9000X3D deals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on June 3, 2025 has an exercise price per share equal to $30.91, Vera's closing trading price on June 3, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, 2025, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About VeraVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit For more information, please contact: Investor Contact:Joyce AllaireLifeSci Advisors212-915-2569jallaire@ Media Contact:Debra CharlesworthVera Therapeutics415-854-8051corporatecommunications@
Yahoo
2 hours ago
- Yahoo
AMD price target, Intuitive Surgical downgrade: Trending Tickers
Citi analysts lifted their price target for Advanced Micro Devices (AMD) to $120 from $100, highlighting potential positive catalysts in the second half of the year. Deutsche Bank downgraded Intuitive Surgical (ISRG) to Sell from Neutral and cut its price target for the company to $440. To watch more expert insights and analysis on the latest market action, check out more Wealth here. Now time for some of today's trending tickers. We are watching AMD and Intuitive Surgical. Joining me now, we've got the co-host of Market Domination, Josh Lipton. Josh, let's set the scene for folks first with AMD here. AMD's price target raised to $120 a share from $100 at City. This is ahead of the company's advancing AI day. The firm expects the chip maker to launch its latest AI products later this week and highlight some new customers. Overall analysts expect positive catalyst for AMD heading into the second half of the year, highlighting where the chip maker has some advantages over Nvidia potentially here, Josh. So the interesting about this note, Brad, was they found a lot of good stuff potentially coming for Lisa Su's company, right? I mean, you read through this note. First of all, I thought it was interesting they highlight, hey, it's not just Apple. They're not the only ones with a big tech event this week, right? This is going to be the advancing AI day on June 12th. They expect AMD to launch its latest AI product, highlight new customers, maybe some AWS, maybe even potentially open AI. That would be exciting. They argue AMD does have a few advantages over Nvidia. I thought this part of the note was really interesting. They argue AMD's latest AI product will feature more HBM. They're referring there to high bandwidth memory versus Nvidia's B200 series with substantially lower pricing. Then they talk about even some maybe positive surprises coming up, Brad. They tell their clients about the AI business should ramp for instance in the second half of the year. AMD's Xilinx business, they said should recover. All sounds very exciting, but at the end of the day, they do reiterate a neutral on this one. So they did raise their target as you noted to 120, but they stay on the sidelines. How come? Well, one reason is, they tell clients, quote, we would like more details on AI gross margins and revenue guidance. So they want more financial details, more insight, more info before they would get more bullish. Yeah, shares moving higher right now. 4% will be watching to see what the announcements are. Plus we mentioned Intuitive Surgical. Let's get into that one. Getting a downgrade to sell from hold at Deutsche Bank, citing quote, significant risks to the company's instruments and accessories business here. Taking a look at shares down right now by just shy of 7% right now. Yeah, they get slashed to a sell over there at Deutsche Bank. So they're no longer fans. They're on the sidelines. They say we expect a growing number of Intuitive's customers to explore adoption of remanufactured instruments, given the potentially significant profitability gains. They say about 46% of Intuitive's US INA revenues would be at risk of encroachment by these third-party remanufactured devices. When is this going to be potentially a problem, Brad? Deutsche Bank telling their clients our model assumes no material impact in 2026, but steadily increasing headwinds in 2027 and especially 2028. So they do go to a sell. They do slash their target by the way to 440. Now, most on the street are actually still bullish on the name and they like this thing. There are only two sells, but as we know, that does not mean they're wrong. Yeah, they say within this, about 46% of Intuitive's US INA revenues would be at risk of encroachment by third-party manufactured devices. Not what you want to hear. No, not at all. Josh, thanks so much. Got it. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
AMD price target lift, Apple's WWDC, Chewy downgrade
Market Domination co-host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute. Advanced Micro Devices (AMD) stock gains after Citi lifts its price target to $120 from $100, citing upcoming artificial intelligence (AI) catalysts and advantages over Nvidia (NVDA). Apple (AAPL) is kicking off its Worldwide Developers Conference on Monday, where the company is expected to unveil key software updates. Chewy (CHWY) stock slides after Mizuho downgraded the stock to Neutral from Outperform. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for Yahoo Finance's market minute. US stocks seesaw as investors eye renewed US-China trade talks. Wall Street looking for signs of either side willing to dial down tensions and reach a tariff deal. AMD shares getting a lift as City raises its price target on that stock from 100 to 120. City highlighting potential positive catalyst, the second half of the year and sees the chip maker as having some advantages over Nvidia. The price target change comes ahead of AMD's advancing AI event, which is taking place on June 12th. Apple kicking off its worldwide developers conference on Monday. The iPhone maker offering a look at the changes coming to the company's software products throughout the next year. Apple expected to reveal software and design updates. And Chewy shares, they're sliding as Mizuho hits the stock with a downgrade, lowering its rating from outperform to neutral. Mizuho citing the pet food company's unattractive positioning, noting quote, several potential landmines for the first quarter. And that's your Yahoo Finance market minute. Sign in to access your portfolio
